654 a:4:{s:8:"template";a:5:{s:53:"/var/www/resverlogix_2018/app/views/page/landing.html";b:1;s:20:"page/navigation.html";b:1;s:14:"page/head.html";b:1;s:14:"page/hero.html";b:1;s:14:"page/tail.html";b:1;}s:9:"timestamp";i:1740013674;s:7:"expires";i:1740017274;s:13:"cache_serials";a:3:{s:77:"/var/www/resverlogix_2018/var/templates_c/%%09^09B^09B27DF2%%landing.html.inc";s:32:"5a634cf1feba096880c886635dca92e6";s:74:"/var/www/resverlogix_2018/var/templates_c/%%AD^AD7^AD761F1B%%head.html.inc";s:32:"ed3ac199bf2b5fc4602464a9eba63514";s:74:"/var/www/resverlogix_2018/var/templates_c/%%BC^BC7^BC746C8E%%tail.html.inc";s:32:"24bce2a9a05a432e68e31c2ba026ae86";}}{nocache:5a634cf1feba096880c886635dca92e6#0}

Science & Programs

Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.

  • Apabetalone

    The world leader in a new class of drugs designed to regulate disease-associated epigenetics.

  • Clinical Trials

    BETonMACE – a global Phase 3 clinical trial with the most advanced epigenetic drug outside of oncology.

  • Partnership Strategy

    Providing novel science, clinical and value-based health solutions to key stakeholders, including payer groups.

  • Investors

    Resverlogix (TSX: RVX), founded in 2001 by Donald McCaffrey and Norman Wong, focuses on the development of therapeutics for disease states with high unmet medical need.

  • News Releases

    Latest($params);?>
  • {nocache:5a634cf1feba096880c886635dca92e6#1}